铁剂加促红细胞生成素治疗幼儿缺铁性贫血临床效果评价  

The clinical effects observation of recombinant human erythropoietin and ferralium on the treatment to the iron-deficiency anemia of infants

作　　者：卢洪萍[1] 杨君平[1] 罗芳[1] 张凌姿[1] 

机构地区：[1]浙江省台州医院临海院区儿科,台州317000

出　　处：《海峡药学》2010年第10期105-107,共3页Strait Pharmaceutical Journal

摘　　要：目的观察铁剂加重组促红细胞生成素治疗幼儿缺铁性贫血的临床疗效。方法 20例患儿(治疗组)接受了重组人红细胞生成素;同期20例患儿作为对照组治疗,两组患儿同时服用铁剂。结果治疗后两组血红蛋白量均高于治疗前,治疗8周后治疗组血红蛋白量高于对照组,两组比较差别有显著性(P<0.05)。同时治疗后两组红细胞压积均高于治疗前,治疗8周后治疗组红细胞压积明显高于对照组,两组比较有显著性差异(P<0.05)。结论应用铁剂治疗时加用重组人红细胞生成素能更为有效治疗缺铁性贫血,快速提高血红蛋白等各项指标,值得临床推广。OBJECTIVE To observe the clinical effects of recombinant human erythropoietin and ferralium on the treatment to the iron-deficiency anemia.METHODS 20 cases with iron-deficiency anemia were treated by recombinant human erythropoietin,and all the 40 cases were treated by the ferralium.RESULTS The postnatal declines of hemoglobin and hematocrit were lessened in the treatment group of the treatment group（P〈0.05）.CONCLUSION Recombinant human erythropoietin and ferralium can prevent and treat anemia effectively,also can limit transfusion as mush as possible,so it is worth to clinical promote.

关 键 词：幼儿 缺铁性贫血 促红细胞生成素 铁剂 

分 类 号：R969.4[医药卫生—药理学]